PERMISSIVE OMICRON BREAKTHROUGH INFECTIONS IN INDIVIDUALS WITH BINDING OR NEUTRALIZING ANTIBODIES TO ANCESTRAL SARS-CoV-2
PERMISSIVE OMICRON BREAKTHROUGH INFECTIONS IN INDIVIDUALS WITH BINDING OR NEUTRALIZING ANTIBODIES TO ANCESTRAL SARS-CoV-2
ABSTRACT BackgroundBreakthrough infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has occurred in populations with high vaccination rates. These infections are due to sequence variation in the spike protein leading to a reduction in protection afforded by the current vaccines, which are based on the original Wuhan-Hu-1 strain, or by natural infection with pre-Omicron strains. MethodsIn a longitudinal cohort study, pre-breakthrough infection sera for Omicron breakthroughs (n=12) were analyzed. Assays utilized include a laboratory-developed solid phase binding assay to recombinant spike protein, a commercial assay to the S1 domain of the spike protein calibrated to the World Health Organization (WHO) standard, and a commercial solid-phase surrogate neutralizing activity (SNA) assay. All assays employed spike protein preparations based on sequences from the Wuhan-Hu-1 strain. Participant demographics and clinical characteristics were captured. ResultsPre-breakthrough binding antibody (bAB) titers ranged from 1:800-1:51,200 for the laboratory-developed binding assay, which correlated well and agreed quantitatively with the commercial spike S1 domain WHO calibrated assay. SNA was detected in 10/12 (83%) samples. ConclusionsNeither high bAB nor SNA were markers of protection from Omicron infection/re-infection. Laboratory tests with antigen targets based on Wuhan-Hu-1 may not accurately reflect the degree of immune protection from variants with significant spike protein differences. Omicron breakthrough infections are likely due to high sequence variation of the spike protein and reflect incomplete immune protection from previous infection with strains that preceded Omicron or with vaccinations based on the original Wuhan-Hu-1 strain.
Williams Erin、Colson Jordan、Hoffer Michael、Andrews David、Krammer Florian、Valiathan Ranjini、Pallikkuth Suresh、Carre?o Juan Manuel、Pahwa Savita
Department of Otolaryngology, University of Miami Miller School of Medicine||Department of Biomedical Engineering, University of MiamiDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of MedicineDepartment of Otolaryngology, University of Miami Miller School of Medicine||Department of Neurological Surgery, University of Miami, Miller School of MedicineDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of MedicineDepartment of Microbiology, Icahn School of Medicine at Mount Sinai||Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai||Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount SinaiDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of MedicineDepartment of Microbiology and Immunology, University of Miami Miller School of MedicineDepartment of Microbiology, Icahn School of Medicine at Mount Sinai||Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount SinaiDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine
医学研究方法医药卫生理论基础医学
Williams Erin,Colson Jordan,Hoffer Michael,Andrews David,Krammer Florian,Valiathan Ranjini,Pallikkuth Suresh,Carre?o Juan Manuel,Pahwa Savita.PERMISSIVE OMICRON BREAKTHROUGH INFECTIONS IN INDIVIDUALS WITH BINDING OR NEUTRALIZING ANTIBODIES TO ANCESTRAL SARS-CoV-2[EB/OL].(2025-03-28)[2025-08-02].https://www.medrxiv.org/content/10.1101/2022.04.17.22273938.点此复制
评论